Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials

Inzucchi, 2012, Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetes Care, 35, 1364, 10.2337/dc12-0413 White, 2013, Alogliptin after acute coronary syndrome in patients with type 2 diabetes, N Engl J Med, 369, 1327, 10.1056/NEJMoa1305889 Scirica, 2013, SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus, N Engl J Med, 369, 1317, 10.1056/NEJMoa1307684 Jadad, 1996, Assessing the quality of reports of randomized clinical trials: is blinding necessary?, Control Clin Trials, 17, 1, 10.1016/0197-2456(95)00134-4 Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 Begg, 1994, Operating characteristics of a rank correlation test for publication bias, Biometrics, 50, 1088, 10.2307/2533446 Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629 Moher, 2009, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, Ann Intern Med, 151, 264, 10.7326/0003-4819-151-4-200908180-00135 Scirica BM, Raz I, Cavender MA, Steg PG, Hirshberg B, Davidson J, et al., on behalf of the SAVOR-TIMI 53 Steering Committee and Investigators. Outcomes of patients with type 2 diabetes and known congestive heart failure treated with saxagliptin: Analyses of the SAVOR-TIMI 53 Study. Poster number 5082 presented at American Heart Association 2013, Dallas, Texas, USA on 17th November 2013. Sokos, 2006, Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure, J Card Fail, 12, 694, 10.1016/j.cardfail.2006.08.211 Nikolaidis, 2005, Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy, Am J Physiol Heart Circ Physiol, 289, H2401, 10.1152/ajpheart.00347.2005 Read, 2011, A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans, Circ Cardiovasc Interv, 4, 266, 10.1161/CIRCINTERVENTIONS.110.960476 Read, 2010, DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease, Circ Cardiovasc Imaging, 3, 195, 10.1161/CIRCIMAGING.109.899377 Ban, 2010, Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor, Endocrinology, 151, 1520, 10.1210/en.2009-1197 Pratley, 2009, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy, Obes Metab, 11, 167, 10.1111/j.1463-1326.2008.01016.x DeFronzo, 2008, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study, Diabetes Care, 31, 2315, 10.2337/dc08-1035 Nauck, 2009, Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study, Int J Clin Pract, 63, 46, 10.1111/j.1742-1241.2008.01933.x Rosenstock, 2010, Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes, Diabetes Care, 33, 2406, 10.2337/dc10-0159 Gomis, 2011, Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study, Diabetes Obes Metab, 13, 653, 10.1111/j.1463-1326.2011.01391.x Taskinen, 2011, Safety and efficacy of linagliptin as add- on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study, Diabetes Obes Metab, 13, 65, 10.1111/j.1463-1326.2010.01326.x Del Prato, 2011, Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial, Diabetes Obes Metab, 13, 258, 10.1111/j.1463-1326.2010.01350.x Owens, 2011, Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study, Diabet Med, 28, 1352, 10.1111/j.1464-5491.2011.03387.x Haak, 2012, Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study, Diabetes Obes Metab, 14, 565, 10.1111/j.1463-1326.2012.01590.x Kawamori, 2012, Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study, Diabetes Obes Metab, 14, 348, 10.1111/j.1463-1326.2011.01545.x Gallwitz, 2012, 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial, Lancet, 380, 475, 10.1016/S0140-6736(12)60691-6 Pfützner, 2011, Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks, Diabetes Obes Metab, 13, 567, 10.1111/j.1463-1326.2011.01385.x Yang, 2011, Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial, Diabetes Res Clin Pract, 94, 217, 10.1016/j.diabres.2011.07.035 Pan, 2012, Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial, Diabetes Metab Res Rev, 28, 268, 10.1002/dmrr.1306 Rosenstock, 2009, Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes, Curr Med Res Opin, 25, 2401, 10.1185/03007990903178735 Hollander, 2011, Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus, Diab Vasc Dis Res, 8, 125, 10.1177/1479164111404575 Chacra, 2011, Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks, Diab Vasc Dis Res, 8, 150, 10.1177/1479164111404574 Barzilai, 2011, Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial, Curr Med Res Opin, 27, 1049, 10.1185/03007995.2011.568059 Hermansen, 2007, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin, Diabetes Obes Metab, 9, 733, 10.1111/j.1463-1326.2007.00744.x Yoon, 2011, Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of beta-cell function in patients with type 2 diabetes, Int J Clin Pract, 65, 154, 10.1111/j.1742-1241.2010.02589.x Vilsbøll, 2010, Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes, Diabetes Obes Metab, 12, 167, 10.1111/j.1463-1326.2009.01173.x Charbonnel, 2006, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone, Diabetes Care, 29, 2638, 10.2337/dc06-0706 Rosenstock, 2006, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo- controlled, parallel-group study, Clin Ther, 28, 1556, 10.1016/j.clinthera.2006.10.007 Aschner, 2006, Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes, Diabetes Care, 29, 2632, 10.2337/dc06-0703 Fonseca, 2013, Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes, J Diabetes Complicat, 27, 177, 10.1016/j.jdiacomp.2012.09.007 Bergenstal, 2010, Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial, Lancet, 376, 431, 10.1016/S0140-6736(10)60590-9 Raz, 2008, Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes, Curr Med Res Opin, 24, 537, 10.1185/030079908X260925 Arechavaleta, 2011, Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial, Diabetes Obes Metab, 13, 160, 10.1111/j.1463-1326.2010.01334.x Wainstein, 2012, Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes, Diabetes Obes Metab, 14, 409, 10.1111/j.1463-1326.2011.01530.x Raz, 2006, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus, Diabetologia, 49, 2564, 10.1007/s00125-006-0416-z Arjona Ferreira, 2013, Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial, Am J Kidney Dis, 61, 579, 10.1053/j.ajkd.2012.11.043 Dobs, 2013, Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes, J Diabetes, 5, 68, 10.1111/j.1753-0407.2012.00223.x Chan, 2008, Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency, Diabetes Obes Metab, 10, 545, 10.1111/j.1463-1326.2008.00914.x Williams-Herman, 2010, Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes, Diabetes Obes Metab, 12, 442, 10.1111/j.1463-1326.2010.01204.x Seck, 2010, Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study, Int J Clin Pract, 64, 562, 10.1111/j.1742-1241.2010.02353.x Strain, 2013, Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study, Lancet, 382, 409, 10.1016/S0140-6736(13)60995-2 Fonseca, 2007, Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes, Diabetologia, 50, 1148, 10.1007/s00125-007-0633-0 Pan, 2012, Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus, Diabetes Obes Metab, 14, 737, 10.1111/j.1463-1326.2012.01593.x Pan, 2008, Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial, Diabet Med, 25, 435, 10.1111/j.1464-5491.2008.02391.x Dejager, 2007, Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study, Horm Metab Res, 39, 218, 10.1055/s-2007-970422 Scherbaum, 2008, Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia, Diabetes Obes Metab, 10, 675, 10.1111/j.1463-1326.2008.00850.x Bolli, 2009, Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin, Diabetes Obes Metab, 11, 589, 10.1111/j.1463-1326.2008.01023.x Ferrannini, 2009, Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy, Diabetes Obes Metab, 11, 157, 10.1111/j.1463-1326.2008.00994.x Rosenstock, 2009, Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus, Diabetes Obes Metab, 11, 571, 10.1111/j.1463-1326.2008.01021.x Foley, 2009, Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes, Horm Metab Res, 41, 905, 10.1055/s-0029-1234042